Cancer Immunotherapy Enhancement Through Nanotechnology

The advent of nanotechnology has revolutionised cancer immunotherapy by enabling precise delivery, controlled release and immune modulation at tumour sites. By engineering nanocarriers—from lipid-based nanoparticles and polymeric gels to prodrug nanovectors—researchers can co-deliver antigens, adjuvants and checkpoint inhibitors to reshape the immunosuppressive tumour microenvironment. These platforms improve antigen presentation to dendritic cells, enhance cytotoxic T-cell infiltration and reduce off-target toxicity, thereby augmenting the efficacy and safety of vaccine strategies, adoptive cell therapies and immune checkpoint blockade. Advanced materials, such as stimulus-responsive hydrogels or injectable nanogels, facilitate spatiotemporal control over immunomodulatory payloads, enabling postoperative and in situ vaccination approaches. Moreover, active targeting mechanisms exploit surface ligands or antibodies to direct nanoparticles to specific immune or tumour cells, maximising local immune activation. Collectively, this convergence of nanomaterials and immuno-oncology holds promise for personalised treatments, reduced systemic side effects and broad application across diverse tumour types.

Research from Nature Portfolio

Recent studies have introduced injectable immunomodulatory nanogels capable of locally depleting suppressive cell populations while releasing immunogenic agents over extended periods. This approach reprogrammes the tumour microenvironment into an immune-stimulatory niche, enhances systemic T-cell memory and prevents recurrence and metastasis in preclinical models. Complementary work has implemented peritumoural, macroporous biomaterial scaffolds that concentrate dendritic cells via incorporated cytokines and immunostimulatory oligonucleotides alongside chemotherapeutic prodrugs. This combinatorial platform drives immunogenic cell death, repolarises tumour-associated macrophages and achieves complete metastasis-free survival after surgical resection. Foundational efforts have also demonstrated personalised hydrogel-based vaccines loaded with immune checkpoint modulators and photosensitisers that, upon near-infrared activation, synchronise antigen release and checkpoint blockade, thereby promoting dendritic cell maturation and robust cytotoxic T-lymphocyte infiltration to prevent relapse.

Cancer Immunotherapy Enhancement Through Nanotechnology publication trend

The graph below shows the total number of articles in cancer immunotherapy enhancement through nanotechnology across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour microenvironment: The complex network of cancer cells, stromal components and immune cells surrounding a tumour that influences immune responses and therapy outcomes.

Nanocarrier: A nanoscale delivery vehicle, such as a liposome or polymeric particle, engineered to transport therapeutic agents to specific cells or tissues.

Immunogenic cell death: A form of tumour cell demise that releases damage-associated molecular patterns and antigens, stimulating antigen-presenting cells.

Dendritic cell: A specialised antigen-presenting immune cell that orchestrates T-cell activation and initiates adaptive immune responses.

Immune checkpoint inhibitor: A therapeutic agent that blocks regulatory pathways (e.g. PD-1/PD-L1) to enhance T-cell-mediated antitumour immunity.

References

1. Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence. Nature Communications (2019).
2. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors. Nature Communications (2020).
3. Engineering Prodrug Nanomedicine for Cancer Immunotherapy. Advanced Science (2020).
4. Emerging Nano‐/Microapproaches for Cancer Immunotherapy. Advanced Science (2019).
5. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. Journal of Hematology & Oncology (2019).
6. Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. Theranostics (2019).
7. Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer. Advanced Science (2020).